Table 2.
Predictors of Antipsychotic Treatment Discontinuation in a Between-Individual Analysis
| Covariate | P Value | AHR | Lower 95% CI | Upper 95% CI |
|---|---|---|---|---|
| Sociodemographic | ||||
| Male gender | <.0001 | 0.83 | 0.77 | 0.88 |
| Age | ||||
| <25 | <.0001 | 1.24 | 1.13 | 1.37 |
| 25–34 | .0067 | 1.14 | 1.04 | 1.25 |
| ≥35a | Reference | |||
| Duration of first hospital stay due to schizophrenia | ||||
| <1 moa | Reference | |||
| 1–2 mo | <.0001 | 0.76 | 0.69 | 0.84 |
| 2–4 mo | <.0001 | 0.68 | 0.62 | 0.75 |
| ≥4 mo | <.0001 | 0.44 | 0.40 | 0.48 |
| History of comorbid psychiatric conditions | ||||
| Substance abuse disorder | <.0001 | 1.30 | 1.18 | 1.42 |
| Suicidality | .0949 | 1.57 | 0.93 | 2.67 |
| Intellectual disability | .0596 | 0.75 | 0.55 | 1.01 |
| History of comorbid medical conditions | ||||
| Cancer | .2669 | 0.76 | 0.46 | 1.24 |
| Cardiovascular disease | .0302 | 0.80 | 0.65 | 0.98 |
| Diabetes | .0731 | 1.48 | 0.96 | 2.28 |
| Asthma/COPD | .101 | 0.84 | 0.68 | 1.03 |
| Co-treatment upon treatment initiation | ||||
| Antidepressant | .4587 | 0.97 | 0.90 | 1.05 |
| Antiparkinsonian | .1063 | 0.78 | 0.58 | 1.05 |
| Benzodiazepine | .4302 | 0.96 | 0.86 | 1.07 |
| Z-drugs | .2869 | 1.11 | 0.92 | 1.34 |
| Lithium | .3852 | 1.09 | 0.90 | 1.32 |
| Mood stabilizer | .7338 | 1.02 | 0.92 | 1.14 |
Note: 95% CI, 95% confidence interval; AHR, adjusted hazard ratio; COPD, chronic obstructive pulmonary disease.
aReference.